Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 14/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12418579 | 0.85 | MMP13 (0.38) | MMP13MMP12SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL6210220 | 0.85 | MMP13 (0.51) | MMP13ADAMTS5MMP12SMN1; SMN2NPSR1 | |
| SCHEMBL941785 | 0.82 | ALDH1A1 (0.44) | MMP13ADAMTS5MMP2MMP14ALDH1A1 | |
| SCHEMBL12378667 | 0.79 | CA12 (0.42) | MMP13ADAMTS5MMP2MMP12CYP2C9 | |
| SCHEMBL12378820 | 0.78 | ADAM17 (0.51) | MMP13ADAMTS5MMP2ALDH1A1 | |
| SCHEMBL941823 | 0.78 | MMP13 (0.46) | MMP13MMP2MMP12SMN1; SMN2MMP14 | |
| SCHEMBL6209887 | 0.73 | MMP13 (0.52) | MMP13MMP2MMP12SMN1; SMN2NPSR1 | |
| SCHEMBL12378835 | 0.72 | SMN1; SMN2 (0.68) | MMP13ADAMTS5MMP2SMN1; SMN2NPSR1 | |
| SCHEMBL13219698 | 0.72 | PLCG1 (0.55) | PLCG1MMP13MMP2CYP1A2CYP3A4 | |
| SCHEMBL12378830 | 0.72 | ADAMTS5 (0.42) | MMP13ADAMTS5MMP2MMP12SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998961-B2 | For treating conditions associated with UDP-3-O (R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | SCHERING CORPORATION | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | LPXN, HAX1, LCT | PLCG1 2367/4885MMP13 1137/4885ADAMTS5 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.